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Abstract 
Background: Since 2005, the Togo National Malaria Control Programme has recommended two different formula-
tions of artemisinin-based combination therapy (ACT), artesunate–amodiaquine (ASAQ) and artemether-lumefantrine 
(AL), for the treatment of uncomplicated malaria. Regular efficacy monitoring of these two combinations is con-
ducted every 2 or 3 years. This paper reports the latest efficacy assessment results and the investigation of mutations 
in the k13 propeller domain.
Methods: The study was conducted in 2012–2013 on three sentinel sites of Togo (Lomé, Sokodé and Niamtougou). 
Children aged 6–59 months, who were symptomatically infected with Plasmodium falciparum, were treated with 
either AL (Coartem®, Novartis Pharma, Switzerland) or ASAQ (Co-Arsucam®, Sanofi Aventis, France). The WHO stand-
ard protocol for anti-malarial treatment evaluation was used. The primary end-point was 28-day adequate clinical and 
parasitological response (ACPR), corrected to exclude reinfection using polymerase-chain reaction (PCR) genotyping.
Results: A total of 523 children were included in the study. PCR-corrected ACPR was 96.3–100 % for ASAQ and 
97–100 % for AL across the three study sites. Adverse events were negligible: 0–4.8 % across all sites, for both arte-
misinin-based combinations. Upon investigation of mutations in the k13 propeller domain, only 9 (1.8 %) mutations 
were reported, three in each site. All mutant parasites were cleared before day 3. All day 3 positive patients were 
infected with k13 wild type parasites.
Conclusions: The efficacy of AL and ASAQ remains high in Togo, and both drugs are well tolerated. ASAQ and AL 
would be recommended for the treatment of uncomplicated malaria in Togo.
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Background
Despite several decades of malaria control efforts, 
malaria-related mortality and morbidity remains a pub-
lic health problem in sub-Saharan countries [1, 2]. In 
Togo, Plasmodium falciparum malaria transmission is 
stable, but with seasonal outbreaks which are equatorial-
type in the south and tropical-type in the north of the 
country. Since 2005, the National Malaria Control Pro-
gramme (NMCP) has recommended two different forms 
of artemisinin-based combination therapy (ACT) for the 
treatment of uncomplicated malaria: artemether–lume-
fantrine (AL) and artesunate–amodiaquine (ASAQ) [3]. 
Severe malaria is treated with injectable artesunate or 
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quinine. To verify the continued efficacy of these two 
artemisinin-based combinations in Togo, efficacy moni-
toring is conducted every 2 or 3  years [4]. On previous 
evaluations conducted in 2005, 2007 and 2009, adequate 
clinical and parasitological response (ACPR), corrected 
for reinfection by polymerase chain reaction (PCR) geno-
typing was about 95 % on all sentinel sites [3].
At a global level, increases in the availability and use 
of ACT, together with the increased use of insecticide-
treated bed nets, have substantially reduced malaria 
burden. Between 2000 and 2015, malaria incidence 
rates decreased by 37 % globally, and by 42 % in Africa. 
During this same period, malaria mortality rates fell by 
60 % globally and by 66 % in the African Region [2]. This 
progress in malaria control is threatened by the rapid 
development and spread of artemisinin resistance [5]. 
Artemisinin resistance is characterized by slow parasite 
clearance [6, 7] due to the reduced susceptibility of ring-
stage parasites [8–12]. Point mutations in the propeller 
region of a P. falciparum kelch (k13) protein have recently 
been linked with artemisinin resistance [13].
This article reports the results of the latest ACT effi-
cacy evaluation carried out in 2012–2013 on three senti-
nel sites, and results from the investigation of mutations 
in the k13 propeller domain.
Methods
This evaluation was conducted in Togo on three of the 
five sentinel sites designated for the surveillance of anti-
malarial treatments (Fig. 1): (1) Cacaveli Medical Centre 
and the District No. 2 Hospital in Lomé (the capital city); 
(2) the Regional Hospital and the Polyclinic in Sokodé 
(350 km north of Lomé) and (3) Doufelgou District Hos-
pital in Niamtougou (425 km north of Lomé). The study 
took place from October to December 2012 in Niamtou-
gou and Sokodé, to coincide with the high malaria trans-
mission season in the north, and from June to August 
2013 in Lomé.
Study design
This was a prospective study of the clinical and parasi-
tological efficacy of ASAQ and AL for the treatment of 
uncomplicated P. falciparum malaria, conducted accord-
ing to the World Health Organization (WHO) standard 
protocol [14].
The sample size calculation was based on an assumed 
efficacy of 95 % for both, artemisinin-based combinations 
a 10 % significance level and a power of 95 %, with 20 % 
in addition, to account for patients who are likely to be 
either lost during follow-up, withdraw or be excluded 
after detection of reinfection with PCR correction [15, 
16].
Patients and treatments
Eligible patients were children aged between six and 
59  months, presenting to the participating health facili-
ties with fever or a history of fever (oral  ≥37.5  °C, 
rectal ≥38 °C) in the last 24 h, who had microscopically-
confirmed P. falciparum mono-infection (parasite den-
sity 2000–250,000 asexual parasites/mm3). Children with 
severe malaria symptoms according to the WHO case 
definition, and symptoms of severe malnutrition and 
chronic diseases, or with mixed Plasmodium infection 
were excluded.
Patients were randomly assigned to receive AL or 
ASAQ, with all doses administered under medical super-
vision. AL (Coartem®, Novartis Pharma, Switzerland) 
was administered as 20 mg artemether/120 mg lumefan-
trine fixed-dose combination tablets twice daily during 
3 days according to body weight: one tablet for 5–14 kg 
and two tablets for 15–24  kg. ASAQ (Co-Arsucam®, 
Sanofi Aventis, France), artesunate (25 or 50  mg) and 
amodiaquine (67.5 or 135  mg), were administered once 
daily during 3  days according to body weight: 25  mg 
artesunate/67.5  mg amodiaquine tablets for 5–8  kg 
and 50  mg artesunate/135  mg amodiaquine tablets for 
Fig. 1 Sentinel sites for surveillance of the efficacy of artemisinin-
based combination therapy in Togo
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9–17 kg. As antipyretic, 60 mg/kg of Paracetamol per day 
during the first 3 days (day 0 to day 2) was given system-
atically to every child included in the study.
Children enrolled in the cohort received drug treat-
ment on days 0, 1 and 2, with follow up on days 3, 7, 14, 
21 and 28. Adverse events were screened and recorded at 
each visit. Clinical examination, including fever assess-
ment, was performed on days 1, 2, 3, 7, 14, 21 and 28. 
Capillary blood was taken for parasite counts and assess-
ment of haemoglobin levels were performed at screening 
(day 0) and at days 2, 3, 7, 14, 21 and 28. Haemoglobin 
level was measured using a point-of-care testing: the 
HemoCue® Hb 301 System (HemoCue AB, Ängelholm, 
Sweden). Asexual parasitaemia was determined from 
Giemsa-stained thick blood smears against the number 
of parasites per 200 white blood cells on day 0 and 1000 
at follow-up assessments, based on a putative count of 
6000 white blood cells per microlitre of blood. Gameto-
cytes were similarly enumerated [14].
Dried blood spots were obtained for PCR at enrolment 
(day 0) and on follow-up days 1, 2, 3, 7, 14, 21 and 28. 
In the case of parasitaemia detected after day 7, to dis-
tinguish between recrudescence and reinfection, PCR 
genotyping was performed on paired dried blood spots 
to determine polymorphisms in merozoite surface pro-
tein-1 (msp-1), merozoite surface protein-2 (msp-2), and 
glutamate-rich protein (glurp) polymorphism, as per 
WHO methods [15].
To assess the treatment effect on parasites mutations 
that modulate treatment response, mutations in k13 
propeller gene—the molecular marker associated with 
decrease in P. falciparum artemisinin sensitivity were 
investigated [5, 13]. The resistance was investigated by 
examining polymorphisms in the k13 propeller domain 
at day 0. The method used was a nested polymerase chain 
reaction (PCR) protocol followed by Sanger sequencing 
using primers specific to P. falciparum. The amplicon 
used for sequencing covered 740 bp, which included the 
k13 propeller domain [13].
Outcomes evaluation and statistical analysis
Treatment outcomes were classified based on parasi-
tological and clinical outcomes assessment as recom-
mended by the WHO [14]. Therapeutic responses on day 
28 were classified as either adequate clinical and para-
sitological response (ACPR), or treatment failure (TF); 
designated as early treatment failure (ETF), late clinical 
failure (LCF), or late parasitological failure (LPF).
The primary outcome measure was ACPR, corrected 
for reinfection using PCR genotyping at day 28. Patients 
were excluded from the analysis for the following rea-
sons: lost to follow-up, protocol violations, treatment 
failure due to reinfection, or type of treatment failure 
could not be determined using PCR. Severe malaria cases 
developed during follow-up were treated with parenteral 
quinine according to the NCMP recommendations.
Data management and analysis were completed with 
Epi Info 6.0.4 adapted to the WHO’s Microsoft® Excel-
based applications [17] that enabled results be analysed 
with per-protocol and Kaplan–Meier methods.
Results
Among 1239 children with fever screened, 523 were 
included in the study (Fig. 2), 50.4 % had negative blood 
smear, and 92 (7.4 %) were not included for the following 
reasons: 63 (5.1 %) for parasitaemia below 2000 parasites/
mm3, 2 (0.2 %) for parasitaemia >250,000 parasites/mm3, 
3 (0.2 %) for signs of severe malaria, 11 (0.9 %) for mixed 
P. falciparum and Plasmodium malariae or Plasmodium 
ovale infection, 6 (0.5  %) for parents refusal to consent, 
and 7 (0.6 %) for children refusal to take medicines.
Mean age was 37.6 and 36.6  months, respectively, 
for ASAQ and AL on the Lomé site, 35.5  months for 
both combinations on the Sokodé site, and 37.8 and 
36.9  months, respectively, for ASAQ and AL on the 
Niamtougou site. At enrolment, the mean temperature 
was between 38.5 and 39.2 °C and geometric mean para-
sitaemia between 23,906 and 38,720/mm3 for all sites and 
treatment groups. Across all sites and treatment groups, 
the sex-ratio was around 1:1 (Table 1).
Fever clearance was observed by day 1 for the major-
ity of participants; the mean temperature decreased from 
38.6  °C on day 0 to 37  °C on day 1 for both combina-
tions across all sites. On day 1, the proportion of children 
with mean temperatures below 37  °C were 79 and 72 % 
in Sokodé, 77 and 65 % in Niamtougou and 74 and 56 % 
Lomé, respectively, for ASAQ and AL.
On day 1, parasite clearance was observed in 90 % of 
children in Sokodé, 77  % in Niamtougou and 92  % in 
Lomé for ASAQ and 92 % of in Sokodé, 86 % in Niam-
tougou and 90 % in Lomé for AL. Parasite clearance was 
achieved by day 3 in all patients in Sokodé and Lomé. 
However, at day 3, parasite clearance was achieved 
in Niamtougou for 94  % of patients receiving ASAQ 
and 96  % of those receiving AL. Gametocyte clear-
ance was similar across the three study sites. For the 
AL treatment group, gametocytes decreased from day 
0 throughout the follow-up days. However, for ASAQ 
gametocytes increased until day 3 before starting to 
decrease, with clearance achieved by day 28 (Fig. 3). The 
proportion of patients that were gametocyte positive 
also decreased with a similar trend as the gametocyte 
clearance (Fig.  4). A consistent increase in mean hae-
moglobin levels of 1.5–2  g/dL by day 28 was observed 
for both artemisinin-based combinations across the 
three sites (Fig. 5).
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Non-PCR-corrected ACPR decreased from the south-
ern to the northern part of the country (Table  2). AL 
efficacy rates were 95.4 % in Lomé, 87.8 % in Sokodé and 
85.5  % in Niamtougou. ASAQ efficacy rates decreased 
from 97.8 % in Lomé to 97.6 % in Sokodé and to 92.8 % 
in Niamtougou. PCR-corrected efficacy rates varied 
from 96.3 to 100  % for ASAQ and 97 to 100  % for AL. 
Treatment failure was slightly higher for AL as com-
pared to ASAQ (Table  2). Niamtougou is the only site 
where PCR-corrected treatment failure for ASAQ was 
recorded. Most of the treatment failures (LCF and LPF) 
were observed on day 14 for AL on Sokodé and Niamtou-
gou sites. Treatment failures for ASAQ only appeared by 
the day 21, while on the Lomé site, the first failures were 
observed on day 21 for AL and day 28 for ASAQ.
Treatment adverse events recorded during the study 
were mild and of low percentage: among the 262 chil-
dren treated with ASAQ and 261 treated with AL, only 4 
(1.5 %) and 7 (2.7 %) cases of mild adverse events, respec-
tively in the ASAQ and AL cohorts (Table 3).
Among the 523 patients, 500 isolates were successfully 
sequenced for the k13 propeller domain. Overall, 491 
(98.2 %) were wild type or presented with synonymous 
mutations. Only 9 (1.8  %) mutations were reported, 
three in each site: S522M, A578S and C532S in Lomé; 
S522C, A578S in Sodoké; and S522C and A578S (n = 2) 
in Niamtougou. All the patients carrying mutant para-
sites cleared their parasites before day 3. In addition, all 
day 3 positive patients were infected with k13 wild type 
parasites.
ACPR: adequate clinical and parasitological response; ETF, early treatment failure; LCF, late 
clinical failure; LPF, late parasitological failure; TF, treatment failures (TF = LCF + LPF) 
Total of 1239 children screened 
397 in Lomé, 450 in Sokodé, 392 in Niamtougou 
716 non-randomized 
523 randomized 
262 assigned to ASAQ 
93 in Lomé, 86 in Sokodé, 83 in Niamtougou 
261 assigned to AL 
90 in Lomé, 88 in Sokodé, 83 in Niamtougou 
16 lost/ excluded 3 lost/ excluded 
259 evaluated on day 28  
(93 Lomé, 83 Sokodé, 83 Niamtougou) 
245 evaluated on day 28  
(87 Lomé, 82 Sokodé, 76 Niamtougou) 
Fig. 2 Study flow
Table 1 General characteristics of study participants for treatment with ASAQ and AL by study site in Togo, 2012–2013
Drug Site N Male/female Mean age,  
months (SD)
Mean temperature,  
°C (SD)
Geometric mean  
parasitaemia, µL−1 (95 % CI)
ASAQ Lomé 93 44/49 37.6 (16.2) 39.1 (0.9) 23,906 (2187–198,250)
ASAQ Sokodé 86 39/47 35.6 (15.1) 38.8 (0.9) 38,720 (2026–240,000)
ASAQ Niamtougou 83 48/35 37.8 (15.4) 38.6 (1.0) 34,242 (2226–235,000)
AL Lomé 90 49/41 36.6 (16.8) 39.1 (0.9) 29,986 (2076–215,786)
AL Sokodé 88 51/37 35.5 (16.5) 38.8 (0.9) 31,824 (2060–230,211)
AL Niamtougou 83 43/40 36.9 (15.3) 38.5 (1.0) 29,685 (2172–224,250)
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Discussion
Following the WHO guidelines, the NMCP of Togo 
is recommending AL and ASAQ for the treatment of 
uncomplicated malaria, since 2005. A monitoring of 
these two artemisinin-based combinations is conducted 
every 2 or 3  years to provide timely information on 
trends of their efficacy and safety to enhance evidence-
based decision making by the NMCP [3, 4].
The results showed that the two combinations induced 
fever clearance as quickly as day 1 following the treat-
ment for more than 50 % of participants across all study 
sites. Complete parasite clearance was observed by 
Fig. 3 Gametocyte clearance by ACT and study site in Togo, 2012–2013
Fig. 4 Proportion of patients that were gametocyte positive from day 0 to day 28, by ACT and study site in Togo, 2012–2013
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day 3 for all participants on two sentinel sites (Sokodé 
and Lomé). Moreover, the gametocytocidal effect was 
observed by the rapid reduction in gametocytes, as early 
as day 1 for AL and from day 3 for ASAQ. With ASAQ, 
the initial increase in the mean gametocytaemia before 
its rapid decrease from day 3 suggests the appearance of 
new gametocytes following initiation of the treatment. 
Nevertheless, complete clearance was achieved by day 28 
for both combinations. Parasites and gametocytes clear-
ances are consistent with the significant improvement of 
haemoglobin levels following treatment.
Beside fever, parasite and gametocytes clearance, 
and improvement of haemoglobin level, efficacy results 
obtained in our study were also very satisfying. The PCR-
corrected therapeutic efficacy of the two forms of arte-
misinin-based combinations recommended by the NMCP 
for uncomplicated malaria cases management in Togo 
remains above the 95 % efficacy threshold recommended 
by the WHO [14]. In addition, the two drugs were both 
well tolerated as less than 5 % of children displayed some 
mild adverse events consisting of diarrhoea, asthenia, 
anorexia, haemoglobinuria, itching, and eyelid oedema.
Studies conducted in the same settings in Togo between 
2005 and 2009 showed the same significant improvement 
of haemoglobin levels following treatment. Moreover, 
the gametocytocidal effect of ACT was observed by the 
initial, rapid reduction in gametocytes. They also showed 
a high therapeutic efficacy: adequate clinical and parasi-
tological response (ACPR), corrected for reinfection by 
PCR genotyping was about 95 % on all sentinel sites. In 
fact, the PCR-corrected 28-day cure rates using the per-
protocol analysis were between 94–100 % for ASAQ and 
96–100 % for AL [3].
The efficacy assessment of ACT has also shown a 
high efficacy level of the combinations in other West 
Africa countries. In Ghana, a bordering country of Togo, 
Abuaku et  al. [18] in a study conducted in 2011, found 
satisfying fever, gametocytes and parasites clearance, 
but in two out of three study sites, and no significant 
improvement in haemoglobin level was observed. PCR-
corrected cure rates on day 28 were 95.4 %. In contrast, 
another study conducted by Abuaku et  al. [19] in 2014, 
demonstrated a satisfactory clearance of fever, gameto-
cytes, and parasites, but significant increase in haemoglo-
bin level. The efficacy rates using the 28 day per-protocol 
analysis were above 95  %: overall PCR-corrected cure 
rates of 100 % for ASAQ and 97.6 % for AL.
In Benin, another bordering country, a 42-day thera-
peutic efficacy study of AL conducted by Ogouyèmi-
Hounto et  al. [20] in 2014 in the northwest of the 
country, showed that fever was significantly cleared by 
day 1, about 90 % of parasites were cleared on day 1 and 
Fig. 5 Change in haemoglobin level at enrolment and during follow-up by ACT and study site in Togo, 2012–2013
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haemoglobin level slightly increased with parasitic clear-
ance. The PCR-corrected cure rate was 100 %.
Results of this study are close to those of other simi-
lar studies conducted in the sub-Saharan African region 
during the last 5  years. These studies also showed high 
efficacy of ACT adopted in the area to treat uncompli-
cated malaria. Mekonnen et al. [21] in a study conducted 
in 2011 in Southwestern Ethiopia, found 97.8  % PCR-
corrected cure rate for AL, with 2.2  % of 28-day game-
tocyte carriage rate. Oguche et  al. [22] noted in their 
study conducted in 2010 in Nigeria, 98.3 and 96.9 % PCR-
corrected cure rates for ASAQ and AL respectively, in 
addition the significant fever and gametocytes clearance, 
and improvement in haematocrit levels. However, much 
higher proportions of adverse events were reported as 
compared to those found in the present study: 37.50  % 
of adverse events in the AL and 46.22  % in the ASAQ 
treatment groups. Ojurongbe et al. [23], in a randomized 
comparative study at the Wesley Guild Hospital, Ilesa 
(Nigeria), found 100 % PCR-corrected cure rates for both 
ASAQ and AL. Complete fever and parasites clearance 
were observed by day 2 and day 3, respectively. But unlike 
this study, much higher proportions of adverse events 
were also reported: 14.8 and 21.8 % of adverse events in 
the AL and ASAQ treatment groups, respectively. Upon 
a review of nine therapeutic efficacy trials conducted in 
Tanzania, Shayo et al. [24] found that the efficacy of both 
AL and ASAQ in Tanzania was high with PCR-corrected 
cure rates of 91–100 and 88–93.8 %, respectively.
Although such high levels of ACT efficacy are found in 
sub-Saharan Africa more than 10 years after its adoption 
in the region, there is a concern of emergence of arte-
misinin resistance in Africa. So far, artemisinin resist-
ance is confined and has been detected in five countries 
in the Greater Mekong Subregion (Cambodia, Lao Peo-
ple’s Democratic Republic, Myanmar, Thailand and Viet-
nam) [5, 6]. In this region, C580Y, R539T, Y493H I543T 
and F446I mutations are most frequently reported [25]. 
This study did not report any mutations associated with 
artemisinin resistance [26]. The A578S mutation that has 
been frequently reported in different countries in Africa, 
but in vitro studies confirmed that this specific mutation 
is not related to artemisinin resistance. Other mutations 
were rarely reported and do not seem to expand clon-
ally in the region. The data presented here do not sug-
gest emergence of artemisinin resistance in Togo despite 
increase day-3 positivity rate in Niamtougou.
Conclusions
Both artesunate–amodiaquine (ASAQ) and artemether–
lumefantrine (AL) have been shown to be safe and highly 
effective in the treatment of uncomplicated P. falciparum 
malaria for children in Togo. No evidence of the emer-
gence of artemisinin resistance in Togo was found upon 
investigation of mutations in the k13 propeller domain. 
The use of these two combinations (ASAQ and AL) 
adopted by health authorities, could be continued for the 
treatment of uncomplicated malaria in Togo.
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